DEF: ALX Oncology 2026 Annual Meeting Proxy Statement

ALX Oncology Holdings Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 10, 2026, to conduct routine governance and compensation votes.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026, at 1:00 p.m. Pacific Time.
• Stockholders will vote on the election of three Class III directors, an advisory vote on executive compensation, and the ratification of KPMG LLP as the independent auditor for 2026.
• The record date for voting is April 15, 2026, with 134,559,917 shares of common stock outstanding.
• The company has adopted a 2025 Inducement Equity Incentive Plan, with an additional 1,300,000 shares reserved for issuance as of January 2026.
• The company reported a net loss of $101,695,000 for the fiscal year ended December 31, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a standard governance filing; while the company is navigating significant financial losses and executive turnover, the proxy focuses on routine administrative and governance matters.

Positives

• The company maintains a strong commitment to stockholder engagement and transparency through virtual meeting accessibility.
• The board of directors maintains a majority of independent directors (five out of seven).
• The company has established a formal Compensation Recovery (Clawback) policy in compliance with SEC and Nasdaq requirements.
• The company successfully completed the appointment of a permanent Chief Medical Officer, Dr. Barbara Klencke, in February 2026.

Negatives

• The company continues to report significant net losses, totaling $101.7 million for fiscal year 2025.
• The say-on-pay advisory vote support declined to 68.64% in 2025 compared to 96.6% in 2024.
• The company has experienced significant turnover in key executive roles, including the President and Chief Scientific Officer and the Chief Medical Officer positions.

Risks

• The company is in a development stage and faces inherent risks related to clinical trial success and regulatory approval.
• The company's reliance on collaboration agreements, such as the one with Tallac Therapeutics, introduces dependency risks.
• The company's ability to continue as a going concern is dependent on its ability to manage cash burn and potentially raise additional capital.
• The classification of the board into three staggered classes may delay or prevent changes in control.

Future Outlook

The company intends to continue advancing its immuno-oncology pipeline, specifically therapies targeting the CD47 checkpoint pathway, while maintaining a focus on cost management and operational efficiency.

Management Comments

• The board believes that the separation of the Chairman and CEO roles reinforces independence and enhances oversight.
• The company is committed to engaging with stockholders and considering their feedback on executive compensation programs.
• The board believes the current composition of the board reflects a commitment to diverse experiences and backgrounds.

Industry Context

StockSavvy.ai notes that ALX Oncology is operating within a highly competitive clinical-stage biotechnology sector where cash preservation and the successful execution of clinical milestones are critical for valuation, especially given the current trend of consolidation and M&A activity in the oncology space.

Comparison to Industry Standards

• The company's executive compensation structure is benchmarked against a peer group of similar clinical-stage biopharmaceutical companies.
• The use of an inducement equity plan is a standard practice for attracting executive talent in the biotechnology industry.
• The company's audit fees are consistent with those of other publicly traded, clinical-stage biotechnology firms.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Consulting agreement between Dr. Jaume Pons and venBio Partners.
• Collaboration and services agreements with Tallac Therapeutics.
• Milestone payments to ScalmiBio stockholders, including Dr. Jaume Pons.

Stakeholder Impact

• Shareholders are asked to vote on director elections and executive compensation.
• Employees are subject to the company's compensation and equity incentive plans.
• Creditors and suppliers are impacted by the company's ongoing cash management and R&D spending.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 10, 2026.
• Tabulate votes for the election of directors and other proposals.
• File a Form 8-K within four business days after the meeting to disclose final voting results.

Key Dates

Recommendation

The filing is a standard annual proxy statement. While it provides transparency into executive compensation and governance, it does not contain material operational or financial news that would typically trigger a significant share price movement.

Keywords

ALX Oncology, ALXO, Proxy Statement, Biotechnology, Oncology, Executive Compensation, Corporate Governance, Clinical Trials